Payment overview · 2025
General Payments
$775.06
30 reported records · 17 companies
Healthcare provider profile · identity verified
Savitha Gowda, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NORWOOD, MA · NPI 1609927276
Verified facts
What the public records show
CMS Open Payments records show Savitha Gowda, M.D. received $775.06 in general payments during 2025 across 30 reported records.
Abbott Laboratories accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 406 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $133.16 | 17.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.22 | 15.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $95.15 | 12.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.55 | 7.3% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.45 | 6.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.90 | 5.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.58 | 5.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.43 | 5.1% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $29.32 | 3.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.38 | 3.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.42 | 3.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.69 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.54 | 2.6% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.41 | 2.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.10 | 2.3% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $16.95 | 2.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.81 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $775.06 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $133.16 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $65.53 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.55 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.42 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $47.45 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $44.90 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.73 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.73 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.73 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.58 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $39.43 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.51 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $29.32 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 406 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 29 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
406 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1053 | 285 |
| Levothyroxine Sodium | Levothyroxine Sodium | 884 | 165 |
| Omeprazole | Omeprazole | 657 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 531 | 126 |
| Metoprolol Succinate | Metoprolol Succinate | 442 | 109 |
| Lisinopril | Lisinopril | 414 | 103 |
| Gabapentin | Gabapentin | 412 | 81 |
| Eliquis | Apixaban | 406 | 47 |
| Losartan Potassium | Losartan Potassium | 394 | 103 |
| Furosemide | Furosemide | 387 | 66 |
| Sertraline Hcl | Sertraline Hcl | 268 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 44 |
| Simvastatin | Simvastatin | 208 | 57 |
| Trazodone Hcl | Trazodone Hcl | 200 | 41 |
| Mirtazapine | Mirtazapine | 191 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 59 |
| Metformin Hcl | Metformin Hcl | 185 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 39 |
| Famotidine | Famotidine | 176 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 171 | 22 |
| Allopurinol | Allopurinol | 167 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 137 | 31 |
| Atenolol | Atenolol | 135 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 57 |
| Glipizide Er | Glipizide | 133 | 31 |
| Potassium Chloride | Potassium Chloride | 116 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 39 |
| Januvia | Sitagliptin Phosphate | 108 | 20 |
| Memantine Hcl | Memantine Hcl | 108 | 17 |
| Metformin Hcl Er | Metformin Hcl | 105 | 20 |
| Donepezil Hcl | Donepezil Hcl | 104 | 24 |
| Tramadol Hcl | Tramadol Hcl | 104 | 30 |
| Ezetimibe | Ezetimibe | 98 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 25 |
| Lorazepam | Lorazepam | 82 | 25 |
| Spironolactone | Spironolactone | 80 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 29 |
| Torsemide | Torsemide | 77 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 70 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 69 | suppressed |
| Verapamil Er | Verapamil Hcl | 67 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 63 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 21 |
| Risperidone | Risperidone | 59 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 16 |
| Prednisone | Prednisone | 58 | 28 |
| Tradjenta | Linagliptin | 57 | suppressed |
| Movantik | Naloxegol Oxalate | 53 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 50 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 50 | 41 |
| Clonazepam | Clonazepam | 50 | 12 |
| Divalproex Sodium | Divalproex Sodium | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 49 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 21 |
| Pregabalin | Pregabalin | 48 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 42 |
| Glipizide | Glipizide | 47 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | suppressed |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Baclofen | Baclofen | 43 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | 11 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 12 |
| Enoxaparin Sodium | Enoxaparin Sodium | 39 | suppressed |
| Finasteride | Finasteride | 39 | 15 |
| Azithromycin | Azithromycin | 38 | 28 |
| Ibuprofen | Ibuprofen | 38 | 14 |
| Linzess | Linaclotide | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 11 |
| Rivastigmine | Rivastigmine Tartrate | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Carvedilol | Carvedilol | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Lactulose | Lactulose | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 30 |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 11 |
| Acyclovir | Acyclovir | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Levemir | Insulin Detemir | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | 12 |
| Valacyclovir | Valacyclovir Hcl | 29 | 15 |
| Clotrimazole | Clotrimazole | 28 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 24 |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Prazosin Hcl | Prazosin Hcl | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Amoxicillin | Amoxicillin | 25 | 22 |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 16 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nystatin | Nystatin | 22 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Armour Thyroid | Thyroid,pork | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Erythromycin | Erythromycin Base | 16 | 11 |
| Heparin Sodium | Heparin Sodium,porcine | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 14 |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $775.06 · 30 records | Abbott Laboratories | ABRYSVO, ACCRUFER, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, FUROSCIX, INTELLIS ADAPTIVESTIM, JARDIANCE, Kerendia, LAGEVRIO, LEQVIO, NEFFY, NURTEC ODT, NUZYRA, Ozempic, PREVNAR 20, QULIPTA, REXULTI, SYNTHROID, UBRELVY, Wegovy | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error